Evonik starts construction of US$220 million lipid innovation center in Lafayette
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
This artificial RNA ligase has higher thermostability than natural RNA ligase
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated